Skin involvement in scleroderma - Where histological and clinical scores meet

Rheumatology

Volumn 46, Issue 5, 2007, Pages 833-841

  Verrecchia, Franck ^a   Laboureau, J ^a   Verola, O ^a   Roos, N ^a   Porcher, R ^a   Bruneval, P ^b   Ertault, M ^a   Tiev, K ^c   Michel, L ^a   Mauviel, A ^a   Farge, Dominique ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Fibrosis; Haematopoietic stem cell transplantation; Smad signalling; Systemic sclerosis; TGF

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 1 A2; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISOLONE; RAPAMYCIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ALPHA 2(I) COLLAGEN; COLLAGEN; SERPINE1 PROTEIN, HUMAN; SMAD PROTEIN; SMAD3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXTRACELLULAR MATRIX; FEMALE; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCLERODERMA; SCORING SYSTEM; SKIN BIOPSY; SKIN FIBROBLAST; SKIN FIBROSIS; STATISTICAL SIGNIFICANCE; BIOPSY; BIOSYNTHESIS; CELL CULTURE; DIFFUSE SCLERODERMA; DOUBLE BLIND PROCEDURE; ENZYME IMMUNOASSAY; FIBROBLAST; FIBROSIS; GENETICS; HOSPITALIZATION; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN;

ADULT; AGED; BIOPSY; CELLS, CULTURED; COLLAGEN; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; SCLERODERMA, DIFFUSE; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SKIN; SMAD PROTEINS; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 34347231354     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel451     Document Type: Article

References (37)

1. Furst D, Clements PJ. Hypothesis for the Pathogenesis of SSc. J Rheumatol 1997;24:53-7.
2. Subcommittee for scleroderma criteria of the american rheumatism association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
3. Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am 1996;22:647-74.
4. Clements P, Lachenbruch P, Seibold JR et al. Inter- and intraobserver variability of total skin thickness score (modified Rodan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
5. Scussel-Lonzetti L, Joyal F, Raynauld JP et al. Predicting mortality in systemic sclerosis: Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002;81:154-67.
6. Steen VD, Medsger TA, Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
7. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998;41:1215-20.
8. White B, Moore WC, Wigley FM et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
9. Griffiths B, Miles S, Moss H et al. Systemic sclerosis and interstitial lung disease: A pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography soan and lung function. J Rheumatol 2002;29:2371-8.
10. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in sclerodema lung disease. N Engl J Med 2006;354;2655-66.
11. Fargo D, Passweg J, Van Lear JM et al. Autologous stem cell transplantation in the treatment of systemic sclerosis. A report from the EBMT-EULAR registry. Ann Rheum Dis 2004;63:974-81.
12. McSweeney PA, Nash RA, Sullivan KM et al. High-dose immunosuppressive therapy for severe systemic sclerosis: Initial outcomes. Blood 2002;100:1602-10.
13. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979;22:130-40.
14. Trojanowska M. What did we learn by studying scleroderma fibroblasts? Clin Exp Rheumatol 2004;22:S59-63.
15. Dziadzio M, Smith RE, Abraham DJ et al. Serological assessment of type I collagen burden in scleroderma spectrum disorders: A systematic review. Clin Exp Rheumatol 2004;22:356-67.
16. Verrecchia F, Mauviel A. Control of connective tissue gene expression by TGF beta: Role of Smad proteins in fibrosis. Curr Rheumatol Rep 2002;4:143-9.
17. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: Role in extraoallular matrix gone expression and regulation. J Invest Dermatol 2002;118:211-5.
18. ten Dijka P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004;29:265-73.
19. Shi Y, Massague J. Mechanisms of TGF-beta signaling from call membrane to the nucleus. Cell 2003;113:685-700.
20. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425;577-84.
21. Farge D, Marolleau JP, Zohar S et al. For the Intensification at Autogreffe dens les Maladies Auto Immunes Résistantes (ISAMAIR) study group. Autologous bone marrow transplantation in systemic sclerosis: early results from a multicenter phase I-II study. Br J Hematol 2002;119:726-39.
22. Dennier S, Itoh S, Vivian D et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gone. EMBO J 1998;17:3091-100.
23. Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/ promoter transactivation approach. J Biol Chem 2001;276:17058-62.
24. Sakkas LI, Platsoucas CD, Is systemic sclerosis an antigen driven T call disease? Arthritis Rheum 2004;50:1721-33.
25. Farge D, Henegar C, Carmagnat M et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 2005;52:1555-63.
26. Whitfield ML, Finlay DR, Murray JI et al. Systemic and call type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100:12319-24.
27. Furst DE, Clements PJ, Steen VD, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84-8.
28. Torres JE, Sanchez JL. Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol 1998;20:242-5.
29. Varga J, Brenner DA, Phan SH. Fibrosis Research, Methods and Protocol, Humans Press, 2005.
30. Clements PJ, Lachenbruch PA, Ng SC et al. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990;33:1256-63.
31. Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
32. Chen SJ, Yuan W, Lo S et al. Interaction of smad3 with a proximal smad-binding element of the human alpha2(1) procollagen gene promoter required for transcriptional activation by TGF-beta. J Cell Physiol 2000;183:381-92.
33. Yuan W, Varga J. Transforming growth factor-beta repression of matrix metalloprotainase-1 in dermal fibroblasts involves Smad3. J Biol Chem 2001;276:38502-10.
34. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003;48:1964-78.
35. Dong C, Zhu S, Wang T et al. Deficient Smad7 expression: A putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002;99:3908-13.
36. Denton CP, Abraham DJ. Transgenic analysis of scleroderma: Understanding key pathogenic events in vivo. Autoimmun Rev 2004;3:285-93.
37. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.